PERCEPTIVE ADVISORS LLC (EDELMAN JOSEPH) purchased $7.5M of IMTX (indirect holdings)

Immatics reported Q3 2026 results, highlighting progress in its SUPRAME Phase 3 trial for anzu-cel (IMA203) in advanced melanoma, with enrollment on track to complete by year-end. Topline data is expected in H1 2027, followed by a BLA submission. The company also presented updated Phase 1 data for IMA203CD8 and IMA402 at ESMO Congress 2026, showing promising anti-tumor activity. Immatics had $536.3 million in cash as of September 30, 2026, projecting runway into Q4 2028.

Immatics N.V. (IMTX) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 PRELIMINARY NOTE The unaudited interim condensed Consolidated Financial Statements for the three- and nine-month period ended September 30, 2026, included herein, have been prepared in accordance with International Accounting Standard 34 (“Interim Financial Reporting

Immatics N.V. (IMTX) reported Phase 1 data for IMA402 and IMA203CD8, showing 32% cORR in PRAME-high melanoma and 41% cORR across tumors, respectively. Both treatments demonstrated manageable safety profiles. The company plans to advance development across multiple solid tumor indications, including melanoma and gynecologic cancers.

Immatics N.V. (IMTX) reported updated clinical trial data for IMA402 and IMA203CD8. IMA402 showed a 32% cORR and 91% 1-year OS in advanced melanoma patients. IMA203CD8 achieved a 55% cORR in gynecologic cancers with a median DOR of 8.4 months. Both treatments demonstrated favorable safety profiles. The data were presented at the ESMO 2026 meeting.

Stifel initiated coverage of Immatics with a Buy rating and $15 price target, implying 119.6% upside from the Oct 13 close. The firm cites positive clinical trial outlook and strong market positioning for anzu-cel therapy, expected to launch in early 2028.

Immatics (IMTX) raised $161.1 million via an equity offering, including 15.5 million shares and pre-funded warrants. Proceeds will fund R&D, manufacturing, and potential commercialization of its oncology pipeline, as well as general corporate purposes.